Please use this identifier to cite or link to this item:
Type
ArticleCopyright
Open access
Embargo date
2020-11-01
Collections
- INI - Artigos de Periódicos [3646]
- IOC - Artigos de Periódicos [12968]
Metadata
Show full item record
TARGET PRODUCT PROFILE FOR A TEST FOR THE EARLY ASSESSMENT OF TREATMENT EFFICACY IN CHAGAS DISEASE PATIENTS: AN EXPERT CONSENSUS
Parasitic diseases
Trypanosoma cruzi
Diagnostic medicine
Biomarkers
Drug screening
Serology
Treatment guidelines
Author
Affilliation
Abstract
Six to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing Chagas disease. However, only a small fraction of patients are properly diagnosed and treated. Benznidazole (BNZ) and nifurtimox (NFX) are the first-line antiparasitic treatments currently available, both with long administration regimens (60 days) that can produce adverse side effects. Despite the fact they are not 100% effective in patients with chronic disease, they are the only drugs currently registered, and the benefits of their administration have been confirmed in several clinical studies. Currently, clinical trials with new compounds, using alternative regimens that aim to maintain efficacy whilst reducing toxicity, are ongoing and could lead to new therapeutic opportunities and/or policy change. In any case, the absence of a test for the early assessment of treatment efficacy, often called a test of cure (ToC), is a major obstacle to Chagas disease control. Accurately monitoring treatment response would undoubtedly improve patient management and support the conduct of clinical trials. Although treatment efficacy and treatment response may be conceptually different, we are using these terms synonymously for the purpose of the current target product profile (TPP).
Keywords
Chagas diseaseParasitic diseases
Trypanosoma cruzi
Diagnostic medicine
Biomarkers
Drug screening
Serology
Treatment guidelines
Share